<code id='D1A6F2F4BF'></code><style id='D1A6F2F4BF'></style>
    • <acronym id='D1A6F2F4BF'></acronym>
      <center id='D1A6F2F4BF'><center id='D1A6F2F4BF'><tfoot id='D1A6F2F4BF'></tfoot></center><abbr id='D1A6F2F4BF'><dir id='D1A6F2F4BF'><tfoot id='D1A6F2F4BF'></tfoot><noframes id='D1A6F2F4BF'>

    • <optgroup id='D1A6F2F4BF'><strike id='D1A6F2F4BF'><sup id='D1A6F2F4BF'></sup></strike><code id='D1A6F2F4BF'></code></optgroup>
        1. <b id='D1A6F2F4BF'><label id='D1A6F2F4BF'><select id='D1A6F2F4BF'><dt id='D1A6F2F4BF'><span id='D1A6F2F4BF'></span></dt></select></label></b><u id='D1A6F2F4BF'></u>
          <i id='D1A6F2F4BF'><strike id='D1A6F2F4BF'><tt id='D1A6F2F4BF'><pre id='D1A6F2F4BF'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:explore    - browse:46637
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus